Personalized, highly sensitive MRD detection
Our tumor-informed MRD solution, RaDaR® ST, tracks patient-specific somatic mutations in circulating tumor DNA (ctDNA), enabling highly-sensitive detection of residual disease in solid tumors.
- Early efficacy signals in solid tumors
- Enrich trial populations
- Molecular relapse detection months ahead of imaging
- Support for MRD as a surrogate endpoint
*Sensitivity demonstrated across four independent analytical and clinical validation studies, with detection down to 1 ppm under study-specific conditions. LoD95 is 11 ppm.
NeoGenomics Laboratories, Inc. Data on File.
CTA style
Default